Differential effect of exocytic SNAREs on the production of recombinant proteins in mammalian cells
Abstract
Mammalian cells play a dominant role in the industrial production of biopharmaceutical proteins. However, the productivity of producer cells is often hindered by a bottleneck in the saturated secretory pathway, where a sophisticated mechanism of vesicle trafficking is mediated by numerous proteins and their complexes, among which are the cross‐kingdom conserved SNAREs [soluble NSF (N‐ethylmaleimide‐sensitive factor) receptor]. The SNAREs assemble into complexes by means of four interactive α‐helices and, thus, trigger the fusion of transport vesicles with the respective target membranes. We report that the transgenic expression of exocytic SNAREs, which control the fusion of secretory vesicles to the plasma membrane, differentially impacts the secretory capacity of HEK‐293, HeLa, and CHO‐K1 cells. While other exocytic SNAREs have no effect or a negative effect, SNAP‐23 [synaptosome‐associated protein of 23 kDa] and VAMP8 [vesicle‐associated membrane protein 8] specifically increase the production of recombinant proteins when they are ectopically and stably expressed in mammalian cells. The targeted and effective intervention in the secretory capacity of SNARE proteins is a novel engineering strategy, which could lead to the development of new therapies by increasing the production of biopharmaceutical proteins or by boosting the secretion of cell implants in cell therapy initiatives. Biotechnol. Bioeng. 2011; 108:611–620. © 2010 Wiley Periodicals, Inc.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Expression of SNAP-23 and VAMP8 has been shown to improve production of SEAP and monoclonal antibodies in CHO-K1 cells.
“For example, by controlling vesicle docking and fusion, expression of SNAP-23 and VAMP8 has been shown to improve production of SEAP and monoclonal antibodies in CHO-K1 cells (Peng et al., 2011).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Peng et al., 2011
Cited by
Sorted by citations
Therapeutic glycoprotein production in mammalian cells
Lalonde, M.-E., & Durocher, Y. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.04.028 · Cited by 296 · see citing works
- Authors
- Peng, R., Abellan, E., & Fussenegger, M.
- Affiliations
- ETH Zurich (CH)
- University of Basel (CH)
- Corresponding author
- Fussenegger, Martin
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2010-11-10
- Volume
- 108
- Issue
- 3
- Pages
- 611-620
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2110371202
- Cited by
- 61
- References
- 0
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 4 · 2022: 6 · 2021: 2 · 2020: 2 · 2019: 5 · 2018: 5 · 2017: 6 · 2016: 1 · 2015: 11 · 2014: 4 · 2013: 4 · 2012: 2
- FWCI
- 1.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biotechnology and Bioengineering (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- SNAP23, VAMP8, secretory pathway, recombinant protein expression, vesicle fusion, transgene expression, CHO-K1 cells, HEK293 cells, HeLa cells, biopharmaceutical manufacturing, cell therapy
- MeSH terms
- Animals, Biopharmaceutics, Humans, Mammals, Recombinant Proteins, Cell Culture Techniques, Organisms, Genetically Modified, SNARE Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review